Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.42 |
| ▸ | MMP12 | P39900 | 1/20 | 0.42 |
| ▸ | QPCT | Q16769 | 4/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.38 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1876986 | 0.90 | GRIN2B (0.41) | QPCTLGRIN2BQPCTFYNDRD2 | |
| SCHEMBL12634078 | 0.89 | DRD4 (0.42) | QPCTLMMP12QPCTFYNP2RX3 | |
| SCHEMBL14548043 | 0.89 | QPCT (0.44) | QPCTLMMP12QPCTFYNDRD2 | |
| SCHEMBL12634052 | 0.89 | MMP12 (0.52) | QPCTLMMP12QPCTDRD2POLB | |
| SCHEMBL12634084 | 0.89 | QPCT (0.41) | QPCTLMMP12QPCTP2RX3P2RY14 | |
| SCHEMBL12634086 | 0.89 | QPCT (0.41) | QPCTLMMP12QPCTP2RX3P2RY14 | |
| SCHEMBL12633848 | 0.88 | QPCT (0.44) | QPCTLMMP12QPCTDRD2POLB | |
| SCHEMBL12634049 | 0.87 | MMP12 (0.47) | MMP12QPCTDRD2POLB | |
| SCHEMBL12634056 | 0.87 | DRD2 (0.48) | MMP12QPCTDRD2 | |
| SCHEMBL12634128 | 0.87 | MMP12 (0.39) | QPCTLMMP12QPCTDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7939528-B2 | Heterocycle compounds | GLAXOSMITHKLINE LLC (US) | 2011-05-10 | — | — | US | disclosed |
| US-7939528-B2 | Heterocycle compounds | GLAXOSMITHKLINE LLC (US) | 2011-05-10 | — | — | US | disclosed |
| US-20090054431-A1 | NOVEL HETEROCYCLE COMPOUNDS | GLAXOSMITHKLINE LLC | 2009-02-26 | — | — | US | disclosed |
| US-20090054431-A1 | NOVEL HETEROCYCLE COMPOUNDS | GLAXOSMITHKLINE LLC | 2009-02-26 | — | — | US | disclosed |
| WO-2007047397-A2 | PHENOL ETHERS AS MODULATORS OF THE OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054431-A1 | NOVEL HETEROCYCLE COMPOUNDS | OPRK1, OPRL1, OPRD1 | QPCTL 3091/4885GRIN2B 288/4885MMP12 2506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.